Revolution Medicines Inc (RVMD) Stock Price, Quote & News

Company Profile

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 481 6801

Website: www.revmed.com

Address:

700 Saginaw Drive, Redwood City, United States

AtomicAIerts Dec. 5 at 6:50 AM

$RVMD AtomicAlerts Scalp Alert Direction: SHORT Entry: $78.49 TP1: $77.79 | TP2: $77.09 | TP3: $76.39 Stop Loss: $79.09 👉 https://atomicalerts.com

0 · Reply

Iightning Dec. 5 at 2:01 AM

1ightning® Premium Options Alert (Actionable) Ticker: $RVMD Contract: Dec 19 $80C Entry: 2.80 Exit: 3.64 Return: +29.92% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

boston_drew Dec. 5 at 1:39 AM

$RVMD seems like VSTM results are stronger but with a 20 times less market cap not to mention they have an existing drug what am i missing

0 · Reply

Iightning Dec. 4 at 8:33 PM

1ightning® Premium Options Alert (Actionable) Ticker: $RVMD Contract: Dec 19 $80C Entry: 2.80 Exit: 3.64 Return: +29.92% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

LiquidThetaOptions Dec. 4 at 5:47 PM

💎 LiquidTheta® Live Actionable Trade Asset: $RVMD Contracts: $RVMD January 15, 2027 $80 Calls Scale in: $17.44- $21.31 Scale out: $67.81-$116.25 Profit Potential : 219% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

OptionRunners Dec. 4 at 4:30 PM

$RVMD buyer of the December 19th $80 calls 1,000 times for $2.50

0 · Reply

HedgeAlerts Dec. 4 at 7:09 AM

Hedge Alert Live - Protect Your Portfolio Contract: $RVMD $75.00 Put · DEC 19, 2025 Exp Entry Price: $2.23 - $2.80 Exit Price Target: $4.13 Profit Margin: +85% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Iightning Dec. 4 at 4:16 AM

1ightning® Premium Options Alert (Actionable) Ticker: $RVMD Contract: Dec 19 $80C Entry: 2.90 Exit: 3.93 Return: +35.50% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Irish_lass Dec. 3 at 8:29 PM

$RVMD

0 · Reply

BillionerOfKing Dec. 3 at 3:29 PM

$RVMD Current Stock Price: $77.04 Contracts to trade: $75 RVMD Dec 19 2025 Call Entry: $2.85 Exit: $3.62 ROI: 27% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Revolution Medicines, Inc. (RVMD) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 11, 2025, 10:51 AM EST - 23 days ago

Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript

Nov 5, 2025, 8:41 PM EST - 4 weeks ago

Revolution Medicines, Inc. (RVMD) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 4:02 PM EST - 4 weeks ago

Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

Nov 4, 2025, 4:05 PM EST - 4 weeks ago

Revolution Medicines to Participate in November 2025 Investor Conferences

Oct 29, 2025, 4:05 PM EDT - 5 weeks ago

Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025

Oct 27, 2025, 8:00 AM EDT - 5 weeks ago

Revolution Medicines' RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer

Oct 22, 2025, 12:12 PM EDT - 6 weeks ago

Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor

Oct 16, 2025, 8:00 PM EDT - 7 weeks ago

Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program

Sep 29, 2025, 9:00 AM EDT - 2 months ago

Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer

Sep 11, 2025, 2:14 PM EDT - 3 months ago

Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug

Sep 11, 2025, 1:30 PM EDT - 3 months ago

Revolution Medicines: Shares Soar On Pancreatic Cancer Study Win - I'm Sold

Sep 11, 2025, 8:44 AM EDT - 3 months ago

Revolution Medicines, Inc. (RVMD) Discussion On Metastatic Pancreatic Cancer Update Call (Transcript)

Sep 10, 2025, 4:02 PM EDT - 3 months ago

Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma

Aug 7, 2025, 5:49 AM EDT - 4 months ago

Revolution Medicines, Inc. (RVMD) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:02 PM EDT - 4 months ago

Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress

Jul 30, 2025, 4:05 PM EDT - 4 months ago

Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025

Jul 24, 2025, 4:00 PM EDT - 4 months ago

Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor

Jul 23, 2025, 8:00 AM EDT - 4 months ago

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib

Jul 9, 2025, 8:00 AM EDT - 5 months ago

Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic's AI Discovery Tools to Pursue New Drug Candidates

Jun 30, 2025, 8:00 AM EDT - 5 months ago

Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors

Jun 30, 2025, 8:00 AM EDT - 5 months ago

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

SMMT

Jun 24, 2025, 7:19 AM EDT - 5 months ago

Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug

RPRX

Jun 24, 2025, 7:00 AM EDT - 5 months ago

Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers

Jun 23, 2025, 9:00 AM EDT - 5 months ago

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations

Jun 19, 2025, 11:54 AM EDT - 6 months ago

Revolution Medicines: Positioning Itself To Capture One Of The Largest Cancer Targets In History

May 14, 2025, 8:00 AM EDT - 7 months ago

Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer

May 7, 2025, 6:58 PM EDT - 7 months ago

Revolution Medicines, Inc. (RVMD) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:02 PM EDT - 7 months ago

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

Apr 30, 2025, 4:05 PM EDT - 7 months ago

Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025

Apr 28, 2025, 11:02 AM EDT - 7 months ago

Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday?

Apr 27, 2025, 12:05 PM EDT - 7 months ago

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting

Apr 1, 2025, 4:05 PM EDT - 8 months ago

Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 31, 2025, 4:05 PM EDT - 8 months ago

Revolution Medicines to Participate in April 2025 Investor Conferences

Feb 27, 2025, 9:05 AM EST - 10 months ago

Revolution Medicines, Inc. (RVMD) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:02 PM EST - 10 months ago

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

Feb 24, 2025, 4:05 PM EST - 10 months ago

Revolution Medicines to Participate in March 2025 Investor Conferences

Feb 19, 2025, 4:05 PM EST - 10 months ago

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025

Jan 29, 2025, 4:05 PM EST - 11 months ago

Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Jan 6, 2025, 4:05 PM EST - 11 months ago

Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 5, 2024, 4:05 PM EST - 1 year ago

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 4, 2024, 9:09 AM EST - 1 year ago

Revolution Medicines: Risky Buy On Recent Share Price Dip

Dec 4, 2024, 6:15 AM EST - 1 year ago

Top 3 Health Care Stocks That Could Blast Off In December

ELAN SHC

Dec 3, 2024, 10:38 PM EST - 1 year ago

Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Dec 2, 2024, 4:31 PM EST - 1 year ago

Revolution Medicines Announces Commencement of Public Offering of Common Stock

Dec 2, 2024, 7:30 AM EST - 1 year ago

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

Nov 27, 2024, 4:05 PM EST - 1 year ago

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

Nov 6, 2024, 7:52 PM EST - 1 year ago

Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:02 PM EST - 1 year ago

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

Nov 5, 2024, 9:00 AM EST - 1 year ago

Revolution Medicines to Participate in Upcoming Investor Conferences

AtomicAIerts Dec. 5 at 6:50 AM

$RVMD AtomicAlerts Scalp Alert Direction: SHORT Entry: $78.49 TP1: $77.79 | TP2: $77.09 | TP3: $76.39 Stop Loss: $79.09 👉 https://atomicalerts.com

0 · Reply

Iightning Dec. 5 at 2:01 AM

1ightning® Premium Options Alert (Actionable) Ticker: $RVMD Contract: Dec 19 $80C Entry: 2.80 Exit: 3.64 Return: +29.92% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

boston_drew Dec. 5 at 1:39 AM

$RVMD seems like VSTM results are stronger but with a 20 times less market cap not to mention they have an existing drug what am i missing

0 · Reply

Iightning Dec. 4 at 8:33 PM

1ightning® Premium Options Alert (Actionable) Ticker: $RVMD Contract: Dec 19 $80C Entry: 2.80 Exit: 3.64 Return: +29.92% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

LiquidThetaOptions Dec. 4 at 5:47 PM

0 · Reply

OptionRunners Dec. 4 at 4:30 PM

$RVMD buyer of the December 19th $80 calls 1,000 times for $2.50

0 · Reply

HedgeAlerts Dec. 4 at 7:09 AM

0 · Reply

Iightning Dec. 4 at 4:16 AM

1ightning® Premium Options Alert (Actionable) Ticker: $RVMD Contract: Dec 19 $80C Entry: 2.90 Exit: 3.93 Return: +35.50% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Irish_lass Dec. 3 at 8:29 PM

$RVMD

0 · Reply

BillionerOfKing Dec. 3 at 3:29 PM

0 · Reply

Iightning Dec. 3 at 8:47 AM

1ightning® Premium Options Alert (Actionable) Ticker: $RVMD Contract: Dec 19 $41C Entry: 35.00 Exit: 62.67 Return: +79.06% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Bullish_Team Dec. 2 at 4:12 PM

$RVMD

0 · Reply

BEATOFtheMARKET Dec. 2 at 2:39 PM

$RVMD $RVTY $RXST $RYAAY $RYAN Undeniable Accuracy Cycle Trading Signal plugged into AI 🔥 lists 🔥

0 · Reply

LiquidThetaOptions Dec. 2 at 2:35 PM

💎 LiquidTheta® Live Actionable Trade Asset: $RVMD Contracts: $RVMD January 15, 2027 $80 Calls Scale in: $17.10- $20.90 Scale out: $66.50-$114.00 Profit Potential : 425% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

Iightning Dec. 1 at 10:28 PM

**1ightning® Premium Options Alert (Actionable)** **Ticker:** $RVMD **Contract:** Dec 19 $80C **Entry:** 2.02 **Exit:** 2.68 **Return:** **+32.73% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**

0 · Reply

HedgeAlerts Dec. 1 at 10:02 PM

Hedge Alert Live - Protect Your Portfolio Contract: $RVMD $75.00 Put · DEC 19, 2025 Exp Entry Price: $2.88 - $3.00 Exit Price Target: $5.88 Profit Margin: +104% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Barbann Nov. 27 at 6:39 PM

$RVMD uptick,

0 · Reply

Liondog Nov. 27 at 8:18 AM

$RVPH heard our sp will look like $RVMD pretty soon

2 · Reply

Undervalued0versold Nov. 26 at 10:22 PM

$RVMD yall are in for the correction of the century if $VSTM continues to read out better. Market doesn’t realize this company may no longer have the best in class drugs…Verastem does.

1 · Reply

RealMcCoy Nov. 26 at 5:21 PM

$RVMD give me 80

0 · Reply

TalkMarkets Nov. 26 at 10:56 AM

Is A Final Flush Coming? Here's What The Price Action Is Whispering $SPX $AU $RVMD $COGT https://talkmarkets.com/content/stocks--equities/is-a-final-flush-coming-heres-what-the-price-action-is-whispering?post=540591&userid=166882

0 · Reply

HedgeAlerts Nov. 26 at 2:17 AM

Hedge Alert Live - Protect Your Portfolio Contract: $RVMD $75.00 Put · DEC 19, 2025 Exp Entry Price: $3.50 - $3.60 Exit Price Target: $8.53 Profit Margin: +137% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Market Cap	14.56B
Revenue (ttm)	0.00
Net Income (ttm)	-600.09M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.16

Volume	2,132,800
Avg Vol	2,262,344
Day's Range	N/A - N/A
Shares Out	193.32M
Stochastic %K	94%
Beta	0.96
Analysts	Strong Sell
Price Target	$81.15